- Allozymes raises $15M Series A for European expansion, partnerships.
- Its enzyme platform analyzes 20M variants daily for applications.
- Building AI-powered enzyme library for biocatalytic solutions.
Cashing in for domination
Singapore-based synthetic biotech trailblazer Allozymes has raised a mighty $15 million in a Series A round.
Led by existing investors Seventure Partners and Xora Innovation, the funding also welcomed new backers like Thia Ventures and NUS Technology Holdings.
This cash injection will propel Allozymes’ expansion into Europe and forge strategic partnerships within the food and chemical sectors.
Enzymatic Prowess Unleashed
Allozymes’ secret weapon? Its enzyme screening platform can analyze an astonishing 20 million variants daily, enabling the development of tailored enzymes for industrial applications.
From transforming plant fibers into sugar alternatives to degrading microplastics, Allozymes’ enzymatic wizardry knows no bounds.
Allozymes is building a comprehensive enzyme data library, turbo-charged by AI and machine learning algorithms.
This cutting-edge resource promises to revolutionize biocatalytic solutions across diverse industries, cementing Allozymes’ position as a biotech heavyweight.
To read the original article: https://www.techinasia.com/temasek-backed-allozymes-secures-15m-for-european-expansion
